Skip to content

Quick ratio at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
2.6×+0.3×
LQD
Liquidia CorporationLQDA
-0.9×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
1.5×-3.1×
Arrowhead Research logo
Arrowhead ResearchARWR
6.2×+1.1×
PTC Therapeutics logo
PTC TherapeuticsPTCT
2.4×-1.5×
Scholar Rock logo
Scholar RockSRRK
8.6×-1.6×

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.13B+72.3%

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Calculated from Travere Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s quick ratio?
Travere Therapeutics, Inc. (TVTX) reported quick ratio of 2.9× in Q1 2026.
How has Travere Therapeutics, Inc.'s quick ratio changed year-over-year?
Travere Therapeutics, Inc.'s quick ratio increased by 54.8% year-over-year, from 1.9× to 2.9×.
What is the long-term trend for Travere Therapeutics, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s quick ratio has grown at a -10.1% compound annual growth rate (CAGR), from 4.3× to 2.5×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.